2017
Risk of liver decompensation with cumulative use of mitochondrial toxic nucleoside analogues in HIV/hepatitis C virus coinfection
Re V, Zeldow B, Kallan MJ, Tate JP, Carbonari DM, Hennessy S, Kostman JR, Lim JK, Goetz MB, Gross R, Justice AC, Roy JA. Risk of liver decompensation with cumulative use of mitochondrial toxic nucleoside analogues in HIV/hepatitis C virus coinfection. Pharmacoepidemiology And Drug Safety 2017, 26: 1172-1181. PMID: 28722244, PMCID: PMC5624832, DOI: 10.1002/pds.4258.Peer-Reviewed Original ResearchConceptsHepatitis C virusHIV/HCV patientsHuman immunodeficiency virusHepatic decompensationAntiretroviral therapyHCV patientsCohort studyHazard ratioHIV/hepatitis C virus (HCV) coinfectionChronic hepatitis C virusHepatitis C virus coinfectionHIV/HCV coinfectionHIV-/HCV-coinfected patientsVeterans Aging Cohort StudyC virus coinfectionChronic hepatic injuryAging Cohort StudyRisk of deathToxic nucleoside analoguesMarginal structural modelsHCV coinfectionLiver decompensationART regimensDecompensation eventsHepatic injury
2014
Hepatic decompensation in antiretroviral-treated patients co-infected with HIV and hepatitis C virus compared with hepatitis C virus-monoinfected patients: a cohort study.
Lo Re V, Kallan MJ, Tate JP, Localio AR, Lim JK, Goetz MB, Klein MB, Rimland D, Rodriguez-Barradas MC, Butt AA, Gibert CL, Brown ST, Park L, Dubrow R, Reddy KR, Kostman JR, Strom BL, Justice AC. Hepatic decompensation in antiretroviral-treated patients co-infected with HIV and hepatitis C virus compared with hepatitis C virus-monoinfected patients: a cohort study. Annals Of Internal Medicine 2014, 160: 369-79. PMID: 24723077, PMCID: PMC4254786, DOI: 10.7326/m13-1829.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnti-Retroviral AgentsAscitesBacterial InfectionsCarcinoma, HepatocellularCoinfectionEsophageal and Gastric VaricesFemaleGastrointestinal HemorrhageHepatitis C, ChronicHIVHIV InfectionsHumansIncidenceLiver NeoplasmsMaleMedication AdherenceMiddle AgedPeritonitisRetrospective StudiesRNA, ViralTreatment OutcomeViral LoadConceptsCo-infected patientsHepatitis C virusHepatic decompensationAntiretroviral-treated patientsCohort studyNonblack raceC virusHepatitis C virus-monoinfected patientsChronic hepatitis C virusHigh rateAntiretroviral therapy eraDetectable HCV RNAIncident hepatic decompensationBaseline hemoglobin levelRetrospective cohort studySpontaneous bacterial peritonitisAdvanced hepatic fibrosisAdvanced liver fibrosisVeterans Health AdministrationDiagnosis of ascitesRate of decompensationTherapy eraHIV RNAVariceal hemorrhageHCV RNARelationship Between Alcohol Use Categories and Noninvasive Markers of Advanced Hepatic Fibrosis in HIV-Infected, Chronic Hepatitis C Virus–Infected, and Uninfected Patients
Lim JK, Tate JP, Fultz SL, Goulet JL, Conigliaro J, Bryant KJ, Gordon AJ, Gibert C, Rimland D, Goetz MB, Klein MB, Fiellin DA, Justice AC, Re V. Relationship Between Alcohol Use Categories and Noninvasive Markers of Advanced Hepatic Fibrosis in HIV-Infected, Chronic Hepatitis C Virus–Infected, and Uninfected Patients. Clinical Infectious Diseases 2014, 58: 1449-1458. PMID: 24569533, PMCID: PMC4001286, DOI: 10.1093/cid/ciu097.Peer-Reviewed Original ResearchConceptsChronic hepatitis C virusAdvanced hepatic fibrosisHuman immunodeficiency virusHepatitis C virusAlcohol use categoriesAlcohol-related diagnosesHIV/HCV-coinfected patientsHepatic fibrosisAlcohol consumptionNonhazardous drinkingBinge drinkingHIV/HCV groupAlcohol Use Disorders Identification Test-Consumption (AUDIT-C) questionnaireVeterans Aging Cohort StudyFIB-4 indexAging Cohort StudyCross-sectional studyHCV groupHCV statusHIV-InfectedUninfected participantsChronic hepatitisUninfected patientsCohort studyLiver disease